



TEXAS DEPARTMENT OF STATE HEALTH SERVICES

EDUARDO J. SANCHEZ, M.D., M.P.H.
COMMISSIONER

1100 W. 49th Street • Austin, Texas 78756
1-888-963-7111 • <http://www.dshs.state.tx.us>

United States Senate Bill 2195, entitled the "Anabolic Steroid Control Act of 2004" was enacted on October 22, 2004. It went into effect 90 days after enactment, which was January 20, 2005. The bill redefined "anabolic steroid" and included a new list of steroids under the new definition. All anabolic steroids, unless specifically exempted by regulation, are Schedule III Controlled Substances.

Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Chapter 481, Health and Safety Code, at least thirty-one days have expired since notice of the above referenced action was published, and in my capacity as Commissioner of the Texas Department of State Health Services, I do hereby order that the Substances androstenediol including $3\beta, 17\beta$ -dihydroxy- 5α -androstane and $3\alpha, 17\beta$ -dihydroxy- 5α -androstane; androstenedione; androstenediol including 1-androstenediol, 1-androstenediol, 4-androstenediol, and 5-androstenediol; androstenedione including 1-androstenedione, 4-androstenedione, and 5-androstenedione; bolasterone; calusterone; delta-1-dihydrotestosterone; furazabol; 13β -ethyl- 17α -hydroxygon-4-en-3-one; 4-hydroxytestosterone; 4-hydroxy-19-nortestosterone; mestanolone; 17α -methyl- $3\beta, 17\beta$ -dihydroxy- 5α -androstane; 17α -methyl- $3\alpha, 17\beta$ -dihydroxy- 5α -androstane; 17α -methyl- $3\beta, 17\beta$ -dihydroxyandrost-4-ene; 17α -methyl-4-hydroxynandrolone; methyldienolone; methyltrienolone; 17α -methyl-delta-1-dihydrotestosterone; norandrostenediol including 19-nor-4-androstenediol ($3\beta, 17\beta$ -dihydroxyestr-4-ene), 19-nor-4-androstenediol ($3\alpha, 17\beta$ -dihydroxyestr-4-ene), 19-nor-5-androstenediol ($3\beta, 17\beta$ -dihydroxyestr-5-ene), and 19-nor-5-androstenediol ($3\alpha, 17\beta$ -dihydroxyestr-5-ene); norandrostenedione including 19-nor-4-androstenedione, and 19-nor-5-androstenedione; norbolethone; norclostebol; normethandrolone; stebolone; and tetrahydrogestrinone including their salts, esters, or ethers be added to Schedule III of the Texas Controlled Substances Act. Schedule III of said Act is hereby amended to read as follows:

SCHEDULE III

Schedule III consists of:

- Schedule III depressants

- Schedule III narcotics

- Schedule III stimulants

- Schedule III anabolic steroids and hormones*

anabolic steroids, including any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and include the following:

(1) androstenediol

(1-1) $3\beta,17\beta$ -dihydroxy- 5α -androstane; and

(1-2) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;

(2) androstenedione (5α -androstane-3,17-dione);

(3) androstenediol--

(3-1) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);

(3-2) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);

(3-3) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene); and,

(3-4) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);

(4) androstenedione--

(4-1) 1-androstenedione ($[5\alpha]$ -androst-1-en-3,17-dione);

(4-2) 4-androstenedione (androst-4-en-3,17-dione); and

(4-3) 5-androstenedione (androst-5-en-3,17-dione);

(5) bolasterone ($7\alpha,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);

(6) boldenone (17β -hydroxyandrost-1,4,-diene-3-one);

(7) calusterone ($7\beta,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);

(8) clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);

(9) dehydrochloromethyltestosterone (4-chloro- 17β -hydroxy- 17α -methyl-androst-1,4-dien-3-one);

- (10) delta-1-dihydrotestosterone (a.k.a. '1-testosterone') (17 β -hydroxy-5 α -androst-1-en-3-one);
- (11) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- (12) drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
- (13) ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- (14) fluoxymesterone (9-fluoro-17 α -methyl-11 β ,17 β -dihydroxyandrost-4-en-3-one);
- (15) formebolone (2-formyl-17 α -methyl-11 α ,17 β -dihydroxyandrost-1,4-dien-3-one);
- (16) furazabol (17 α -methyl-17 β -hydroxyandrostan[2,3-c]-furazan);
- (17) 13 β -ethyl-17 α -hydroxygon-4-en-3-one;
- (18) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- (19) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- (20) mestanolone (17 α -methyl-17 β -hydroxy-5 α -androstan-3-one);
- (21) mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- (22) methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- (23) methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- (24) methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- (25) 17 α -methyl-3 β , 17 β -dihydroxy-5 α -androstane;
- (26) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstane;
- (27) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene.
- (28) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-en-3-one);
- (29) methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- (30) methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
- (31) methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- (32) mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- (33) 17 α -methyl-delta-1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
- (34) nandrolone (17 β -hydroxyestr-4-en-3-one);
- (35) norandrostenediol--
 - (35-1) 19-nor-4-androstenediol (3 β , 17 β -dihydroxyestr-4-ene);
 - (35-2) 19-nor-4-androstenediol (3 α , 17 β -dihydroxyestr-4-ene);
 - (35-3) 19-nor-5-androstenediol (3 β , 17 β -dihydroxyestr-5-ene); and
 - (35-4) 19-nor-5-androstenediol (3 α , 17 β -dihydroxyestr-5-ene);
- (36) norandrostenedione—
 - (36-1) 19-nor-4-androstenedione (estr-4-en-3,17-dione); and

- (36-2) 19-nor-5-androstenedione (estr-5-en-3,17-dione;
(37) norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
(38) norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
(39) norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
(40) normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
(41) oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
(42) oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);
(43) oxymetholone (17 α -methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-androstan-3-one);
(44) stanozolol (17 α -methyl-17 α -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
(45) stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
(46) testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone);
(47) testosterone (17 β -hydroxyandrost-4-en-3-one);
(48) tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
(49) trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and
(50) any salt, ester, or ether of a drug or substance described in this paragraph.

- Schedule III hallucinogenic substances

Changes to the schedules are designated by an asterisk (*).

Done in Austin, Texas this 15th day of April, 2005 in witness whereof I
hereunto set my hand and seal of office.



Eduardo J. Sanchez, M.D., M.P.H.
Commissioner